Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154284 | 0.84 | PTGDR2 (0.59) | PTGDR2CETP | |
| SCHEMBL152603 | 0.83 | PTGDR2 (0.39) | PTGDR2CYP11B1CYP11B2F11KLKB1 | |
| SCHEMBL143479 | 0.82 | PTGDR2 (0.44) | PTGDR2CYP11B1CYP11B2F11KLKB1 | |
| SCHEMBL1922197 | 0.82 | PTGDR2 (0.58) | PTGDR2 | |
| SCHEMBL3363821 | 0.81 | PTGDR2 (0.47) | PTGDR2L3MBTL1CETP | |
| SCHEMBL150113 | 0.81 | PTGDR2 (0.57) | PTGDR2CETP | |
| SCHEMBL152200 | 0.81 | PTGDR2 (0.38) | PTGDR2CYP11B1CYP11B2L3MBTL1POLB | |
| SCHEMBL1922822 | 0.80 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL150564 | 0.78 | PTGDR2 (0.51) | PTGDR2CETP | |
| SCHEMBL150211 | 0.77 | PTGDR2 (0.63) | PTGDR2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP11B1 173/4885CYP11B2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.